Remove 2010 Remove Doctors Remove Therapies
article thumbnail

Not all neoantigens are created equal

Drug Target Review

In most cancers, the tumour evolves by acquiring mutations that confer growth advantages or resistance to therapies. However, if the therapy targets only the subclonal (branch) mutations, this will result in the mere ‘pruning’ of specific branches rather than elimination of the whole cancer.

article thumbnail

Mediating BRAF-mutant melanoma resistance

Drug Target Review

Regarding therapy resistant melanomas, why is the alteration of the epigenetic landscape considered significant, and what has been lacking in terms of validated targetable epigenetic mechanisms? What is remarkable here is that we show that the addition of corin to BRAFi-resistant tumour cells resensitises them to BRAFi therapies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

With retinal images and genetic data, researchers predict cardiovascular, metabolic, and other disease risks

Broad Institute

The study also provides insight into the genes and biological pathways that determine retinal health, which could be leveraged to develop future therapies, the researchers say. Altogether, the team identified 259 genetic loci that were associated with retinal thickness.

Disease 124
article thumbnail

Basel: a centre for ground-breaking oncology 

Drug Discovery World

targeted antibody-drug conjugate (ADC) SOT102 and BOXR1030, a GPC3-targeted CAR-T based on proprietary technology designed to improve on the efficacy of CAR T therapies in the tumour microenvironment. These soluble TCR products do not require costly personalised therapy in the way that TCR-T cell treatments do. . He has worked for F.

article thumbnail

The art and science of drug formulation

Drug Target Review

6 On a larger scale, advanced drug delivery systems are already offering more targeted, effective and convenient therapies. Tailored therapies, with formulations based on an individual’s unique profile, promise to optimise treatment efficacy and minimise side effects by targeting specific variations that influence a drug’s response.

Science 59
article thumbnail

Gianluca Pirozzi, MD, PhD, Celebrated for Dedication to the Field of Immunology and Rare Disease Research

The Pharma Data

Dr. Pirozzi received a Doctorate of Medicine from Università Campus Bio-Medico di Roma in Italy, a Doctorate of Philosophy in Immunology from Sapienza Università di Roma in Italy, a Post-Doctorate degree in Immunology from the Institut Pasteur in Paris, France, and business training at the London Business School, UK.

Disease 52
article thumbnail

AstraZeneca Appoints Dr. Susan Galbraith as Executive Vice President, Oncology Research & Development

The Pharma Data

Dr. Susan Galbraith joined AstraZeneca in 2010 and led the development of some of the Company’s most innovative cancer therapies. In 2017, she was awarded an honorary Doctorate of Medical Science from the Institute of Cancer Research (ICR), and in 2018 was admitted to the Fellowship of the Academy of Medical Sciences.